

8. Davidoff F. Standing statistics right stand up. *Ann Internal Med.* 1999;12(130):1019–21.
9. OECD. Health at a Glance: Europe 2014. OECD Publishing; 2014, http://dx.doi.org/10.1787/health_glance_eur-2014-en.
10. OECD. Health at a Glance 2019: OECD Indicators. Paris: OECD Publishing; 2019, <http://dx.doi.org/10.1787/4dd50c09-en>.
11. Pessoa E, Bárbara C, Viegas L, Coata A, Rosa M, Nogueira P. Factors associated with in-hospital mortality from community-acquired pneumonia in Portugal: 2000-2014. *BMC Pulm Med.* 2020;20:18.

V. Hespagnol^{a,*}, Cristina Bárbara^b

^a *Faculdade Medicina do Porto, Porto, Portugal - Centro Hospitalar e Universitário S. João*

^b *Faculdade Medicina de Lisboa - Centro Hospitalar e Universitário Lisboa Norte*

* Corresponding author.

E-mail address: vhespanhol@chs.j.min-saude.pt (V. Hespagnol).

4 September 2020

<https://doi.org/10.1016/j.pulmoe.2020.09.005>

2531-0437/ © 2020 Sociedade Portuguesa de Pneumologia.

Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Interleukin-6 blockade with tocilizumab in COVID-19: Does it live up to its hype?



A recent systematic review by Cortegiani et al.¹ reviewed the evidence and appraised the quality of evidence concerning the use of tocilizumab in patients with coronavirus disease 2019 (COVID-19). Despite a thorough appraisal of a large number of clinical studies (n=28) on tocilizumab in patients with COVID-19, Cortegiani et al.¹ concluded that there is still insufficient evidence on its clinical efficacy in patients with COVID-19 because these studies are associated with a high risk of bias and poor quality. We would like to complement the discussion on the evidence of tocilizumab use in patients with COVID-19.

Interleukin (IL)-6 blocking agents such as tocilizumab have been touted as the potential treatment for COVID-19 since the recognition of the cytokine storm associated with a severe course of COVID-19, which involves increased levels of several cytokines where one of them is IL-6. However, a more pressing question is “Do increased concentrations of an IL-6 imply that its neutralisation will be effective in COVID-19?” While a recent observational study², not included in the systematic review, demonstrated mortality benefits associated with the use of COVID-19, the two recent randomized controlled trials^{3,4} did not replicate the findings. The randomized, double-blinded, placebo-controlled COVACTA trial³ among hospitalized patients with COVID-19 reported no difference in 28-day mortality between the tocilizumab arm and placebo arm (19.7% and 19.4%, respectively). Furthermore, based on the results released on September 18, 2020, from the randomized, double-blind, placebo-controlled EMPACTA trial⁴, there was no statistical difference in 28-day mortality between patients who received tocilizumab and patients who received a placebo (10.4% and 8.6%, respectively).

The findings from randomized controlled trials have proved that the use of tocilizumab in COVID-19 did not live up to the hype, where the increased concentration of IL-6 does not imply that its neutralization will be effective in COVID-19. There is a possibility that the wrong cytokine was targeted to dampen the cytokine storm in COVID-19. A recent prospective study by Blot et al.⁵ compared the

concentrations of IL-6 between 27 patients with COVID-19 pneumonia and 36 patients with non-COVID-19 pneumonia. It was reported that the plasma concentrations of IL-6 were significantly lower in the patients with COVID-19 pneumonia compared to the patients with pneumonia other than COVID-19 (121.0 pg/mL versus 460.4 pg/mL).

The findings of this prospective study, coupled with the findings from two randomized controlled trials that failed to detect mortality benefits with tocilizumab, suggest that IL-6 may not be the cytokine that drives the progression of COVID-19. The use of tocilizumab is not harmless since it may predispose patients to the development of secondary infections. We suggest a shift in focus and to target other mediators of hyperinflammatory state in patients with COVID-19.

Conflicts of interest

The authors have no conflicts of interest.

References

1. Cortegiani A, Ippolito M, Greco M, Granone V, Protti A, Gregoret C, et al. Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review. *Pulmonology.* 2020, <http://dx.doi.org/10.1016/j.pulmoe.2020.07.003> [published online ahead of print, 2020 Jul 20] S2531-0437(20)30153-30157. Online ahead of print.
2. Biran N, Ip A, Ahn J, Go RC, Wang S, Mathura S, et al. Tocilizumab among patients with COVID-19 in the intensive care unit: a multi-centre observational study. *Lancet Rheumatol.* 2020;2:e603–12, [http://dx.doi.org/10.1016/S2665-9913\(20\)30277-0](http://dx.doi.org/10.1016/S2665-9913(20)30277-0).
3. Rosas I, Bräu N, Waters M, Go RC, Hunter BD, Bhagani S, et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. Preprint. *medRxiv.* 2020, 2020.08.27.20183442.
4. Roche. Roche’s phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia. [Accessed 24 September 2020]. <https://www.roche.com/media/releases/med-cor-2020-09-18.htm>.
5. Blot M, Bourredjem A, Biquet C, Piroth L, LYMPHONIE Study Group. Is interleukin 6 the right target in COVID-19 severe pneumonia? *Am J Respir Crit Care Med.* 2020, <http://dx.doi.org/10.1164/rccm.202007-202924LE> [published online ahead of print, 2020 Sep 21].

C.S. Kow^{a,*}, S.S. Hasan^{b,c}

^a School of Postgraduate Studies, International Medical University, Kuala Lumpur, Malaysia

^b Department of Pharmacy, University of Huddersfield, Huddersfield, United Kingdom

^c School of Biomedical Sciences & Pharmacy, University of Newcastle, Callaghan, Australia

*Corresponding author.

E-mail address: chiasiagn_93@hotmail.com (C.S. Kow).

2 October 2020

<https://doi.org/10.1016/j.pulmoe.2020.10.004>

2531-0437/ © 2020 Sociedade Portuguesa de Pneumologia.

Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. Authors' reply



Dear Editor,

We read with interest the Letter from Siang Kow et al.¹ commenting on our systematic review² and their discussion of the preliminary evidence from recent randomized controlled trials (RCTs) on the efficacy and safety of tocilizumab for COVID-19. We concur with the authors that it may indeed be time to divert some of our attention from IL-6 to other mediators of inflammation in COVID-19 patients. In fact, previous pharmacological attempts to modulate the inflammatory response in patients with ARDS and sepsis have repeatedly proven unsuccessful. It is therefore reasonable to also question whether suppressing the pathophysiological inflammatory response, or blocking a single mediator for that matter, will be beneficial for patients with COVID-19.

The authors commented on the absence of significant difference in mortality between patients who received tocilizumab (Actemra/RoActemra) or placebo in the industry funded COVACTA (NCT04320615 - <https://www.roche.com/dam/jcr:6d8de90d-2e31-43c8-b4e1-0a24a2675015/en/29072020-mr-covacta.pdf>) and EMPACTA (NCT04372186 - <https://www.roche.com/media/releases/med-cor-2020-09-18.htm>) trials.

The results of these trials confirm that findings from non-randomized trials should be interpreted with caution and that such caution is warranted particularly during public health emergencies when large numbers of patients may subsequently receive redundant treatments. As discussed by the authors in the context of tocilizumab and exemplified also by the hydroxychloroquine landslide,³ experimental drugs are not always harmless, particularly when indiscriminately used. Patient safety should always be prioritized, which is why experimental drugs must be administered within the framework of registered RCTs that are accompanied by appropriate monitoring and regulation.

Research methodology may have also contributed to the negative findings of the above-mentioned RCTs. One example of a potential determinant of outcome in relation to treatment is the timing of administration in respect to the clinical phase of the disease.⁴ Another is the treatment dose. Case mix may also have diluted the results; there may be sub-populations of COVID-19 patients who do actually benefit from receiving tocilizumab. Hopefully the full reports of the COVACTA and EMPACTA trials will shed some light on

these questions and more. These analyses combined with additional data from the interventional tocilizumab arm of the RECOVERY trial (www.recoverytrial.net) may yet change our perspective on this drug. To summarize, although oft repeated, the following rhetoric is simply the truth: more (high quality) research is urgently needed.

Authors' contribution

AC, MI, SE conceived the content, drafted the manuscript and approved the final version for publication.

Funding

None.

Conflicts of interest

The authors have no conflicts of interest to declare.

References

1. Kow CS, Hasan SS. Interleukin-6 blockade with tocilizumab in COVID-19: Does it live up to its hype? *Pulmonology*. 2020. <http://dx.doi.org/10.1016/j.pulmoe.2020.10.004>.
2. Cortegiani A, Ippolito M, Greco M, Granone V, Protti A, Gregoretto C, et al. Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review. *Pulmonology*. 2020. <http://dx.doi.org/10.1016/j.pulmoe.2020.07.003>. Jul 20:52531-0437(20)30153-7.
3. Cortegiani A, Ippolito M, Ingoglia G, Iozzo P, Giarratano A, Einav S. Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19. *J Crit Care*. 2020;59:176–90. <http://dx.doi.org/10.1016/j.jccr.2020.06.019>.
4. Furlow B. COVACTA trial raises questions about tocilizumab's benefit in COVID-19. *Lancet Rheumatol*. 2020;2(10), e592.

A. Cortegiani^{a,b,*}, M. Ippolito^a, S. Einav^c

^a Department of Surgical, Oncological and Oral Science (Di.Chir.On.S.), University of Palermo, Italy

^b Department of Anesthesia, Intensive Care and Emergency, Policlinico Paolo Giaccone, University of Palermo, Palermo, Italy

^c Intensive Care Unit of the Shaare Zedek Medical Medical Centre, Hebrew University Faculty of Medicine, Jerusalem, Israel